Inhibrx Prepares for Key Insights on INBRX-106 in Phase 2 HNSCC Study

Inhibrx to Present Phase 2 HNSCC Study Results

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker INBX, is set to host a live webcast on September 8, 2026, at 5:00 AM PT. This presentation aims to share the primary endpoint results from the randomized and controlled Phase 2 segment of the HexAgon study, which investigates INBRX-106, a hexavalent OX40 agonist. This drug is evaluated in combination with pembrolizumab compared to pembrolizumab alone in first-line patients suffering from treatment-naïve, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).

The HexAgon study aims to establish the safety and efficacy of INBRX-106, expanding the potential for innovative treatments in oncology. INBRX-106 is designed to enhance T-cell activation, a crucial factor in immune response against cancer cell proliferation. The company strongly believes that this approach could lead to significant advancements in the treatment of HNSCC.

Investors who wish to attend the webcast can do so by accessing this link or by calling (1-888-880-3330) with Conference ID 6981384. A slide presentation will accompany the call and will also be available on Inhibrx's website at https://inhibrx.com/inhibrx-biosciences-inc-investors/.

Following the event, participants can access the presentation through a dedicated link in the "Events and Presentations" section of the Inhibrx website. The webcast will remain available for a period of 60 days, enabling broader access to the information presented.

The Science Behind INBRX-106

INBRX-106 represents the forefront of biopharmaceutical innovation through its unique design as a hexavalent agonist targeting OX40 (CD134), a vital co-stimulatory receptor present on T-cells. The technology stems from Inhibrx's proprietary single-domain antibody (sdAb) platform, allowing for optimal receptor clustering that is essential for effective T-cell activation and longevity. Traditional bivalent antibodies have struggled to achieve this level of receptor engagement, thus highlighting the potential advantages of INBRX-106 in cancer treatment.

Apart from INBRX-106, Inhibrx Biosciences is also dedicated to developing a diverse pipeline of biologic therapeutic candidates. Through the use of advanced protein engineering techniques, they aim to tackle the challenges presented by complex diseases. The clinical pipeline also includes another significant candidate, ozebikbart (INBRX-109), which benefits from similar cutting-edge technology in its design.

Company Background

Inhibrx Biosciences was incorporated in January 2024, as a wholly-owned subsidiary of Inhibrx, Inc. The company focuses on creating innovative therapeutics that meet the stringent needs of complex biological targets. This commitment has led to a strong corporate structure that has enabled Inhibrx to attract both investment and scientific interest rapidly. The company’s vision is to redefine treatment strategies in oncology and beyond, emphasizing efficacy and safety in all its developmental candidates.

For further information on Inhibrx Biosciences and its initiatives, please visit https://www.inhibrx.com.

For additional inquiries, you may contact Kelly Deck, CFO, at [email protected] or by phone at 858-795-4260.